Achillion Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ACHN)

$2.95 0.00 (0.00 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$2.95
Today's Range$2.70 - $3.04
52-Week Range$2.58 - $5.66
Volume1.54 million shs
Average Volume2.07 million shs
Market Capitalization$407.37 million
P/E Ratio-6.02
Dividend YieldN/A
Beta1.32

About Achillion Pharmaceuticals (NASDAQ:ACHN)

Achillion Pharmaceuticals logoAchillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system. The complement system is part of the human innate immune system. Its clinical compound from its complement inhibitor platform is ACH-4471. ACH-4471 is a potent and specific inhibitor of factor D, which demonstrated complete inhibition of the complement alternative pathway in human healthy volunteers in a Phase I clinical trial. The Company has discovered and advanced multiple compounds into clinical development, including sovaprevir, odalasvir, and ACH-3422 in its hepatitis C virus (HCV) program.

Receive ACHN News and Ratings via Email

Sign-up to receive the latest news and ratings for ACHN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:ACHN
CUSIP00448Q20
Phone+1-203-6247000

Debt

Debt-to-Equity RatioN/A
Current Ratio22.66%
Quick Ratio22.66%

Price-To-Earnings

Trailing P/E Ratio-6.02040816326531
Forward P/E Ratio-4.92
P/E GrowthN/A

Sales & Book Value

Annual Sales$15 million
Price / Sales27.11
Cash FlowN/A
Price / CashN/A
Book Value$2.92 per share
Price / Book1.01

Profitability

Trailing EPS($0.49)
Net Income$-61,700,000.00
Net MarginsN/A
Return on Equity-17.84%
Return on Assets-17.21%

Miscellaneous

Employees81
Outstanding Shares137,860,000

Achillion Pharmaceuticals (NASDAQ:ACHN) Frequently Asked Questions

What is Achillion Pharmaceuticals' stock symbol?

Achillion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACHN."

How were Achillion Pharmaceuticals' earnings last quarter?

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced its earnings results on Thursday, February, 22nd. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.16) by $0.00. During the same quarter in the previous year, the business earned ($0.03) EPS. View Achillion Pharmaceuticals' Earnings History.

What guidance has Achillion Pharmaceuticals issued on next quarter's earnings?

Achillion Pharmaceuticals issued an update on its FY18 earnings guidance on Thursday, February, 22nd. The company provided earnings per share guidance of ($0.58-0.55) for the period, compared to the Thomson Reuters consensus earnings per share estimate of ($0.71).

Where is Achillion Pharmaceuticals' stock going? Where will Achillion Pharmaceuticals' stock price be in 2018?

7 equities research analysts have issued 1 year price objectives for Achillion Pharmaceuticals' stock. Their predictions range from $3.50 to $7.00. On average, they anticipate Achillion Pharmaceuticals' stock price to reach $5.00 in the next year. View Analyst Ratings for Achillion Pharmaceuticals.

Who are some of Achillion Pharmaceuticals' key competitors?

Who are Achillion Pharmaceuticals' key executives?

Achillion Pharmaceuticals' management team includes the folowing people:

  • David I. Scheer, Independent Chairman of the Board (Age 64)
  • Milind S. Deshpande Ph.D., President, Chief Executive Officer, Director (Age 60)
  • Mary Kay Fenton CPA, Chief Financial Officer, Executive Vice President (Age 52)
  • Martha E. Manning Esq., , Executive Vice President, General Counsel, Corporate Secretary (Age 62)
  • Joseph Truitt, Executive Vice President, Chief Commercial Officer (Age 52)
  • Jason S. Fisherman M.D., , Independent Director (Age 60)
  • Gary E. Frashier, Independent Director (Age 80)
  • Kurt C. Graves, Independent Director (Age 49)
  • Michael D. Kishbauch, Independent Director (Age 68)
  • Robert L. Van Nostrand, Independent Director (Age 60)

Who owns Achillion Pharmaceuticals stock?

Achillion Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include RTW Investments LP (9.83%), BlackRock Inc. (8.39%), Deutsche Bank AG (1.86%), Sarissa Capital Management LP (1.81%), Rock Springs Capital Management LP (1.63%) and Renaissance Technologies LLC (1.58%). Company insiders that own Achillion Pharmaceuticals stock include & Johnson Johnson, Jason S Fisherman, Joel C Barrish and Mary Kay Fenton. View Institutional Ownership Trends for Achillion Pharmaceuticals.

Who sold Achillion Pharmaceuticals stock? Who is selling Achillion Pharmaceuticals stock?

Achillion Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A., Millennium Management LLC, Wells Fargo & Company MN, Alliancebernstein L.P., Rhumbline Advisers, Creative Planning, Virtu Financial LLC and Raymond James & Associates. View Insider Buying and Selling for Achillion Pharmaceuticals.

Who bought Achillion Pharmaceuticals stock? Who is buying Achillion Pharmaceuticals stock?

Achillion Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including RTW Investments LP, BlackRock Inc., BVF Inc. IL, Renaissance Technologies LLC, Two Sigma Investments LP, Perceptive Advisors LLC, Deutsche Bank AG and Opaleye Management Inc.. Company insiders that have bought Achillion Pharmaceuticals stock in the last two years include Jason S Fisherman, Joel C Barrish and Mary Kay Fenton. View Insider Buying and Selling for Achillion Pharmaceuticals.

How do I buy Achillion Pharmaceuticals stock?

Shares of Achillion Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Achillion Pharmaceuticals' stock price today?

One share of Achillion Pharmaceuticals stock can currently be purchased for approximately $2.95.

How big of a company is Achillion Pharmaceuticals?

Achillion Pharmaceuticals has a market capitalization of $407.37 million and generates $15 million in revenue each year. The biopharmaceutical company earns $-61,700,000.00 in net income (profit) each year or ($0.49) on an earnings per share basis. Achillion Pharmaceuticals employs 81 workers across the globe.

How can I contact Achillion Pharmaceuticals?

Achillion Pharmaceuticals' mailing address is 300 George St, NEW HAVEN, CT 06511-6624, United States. The biopharmaceutical company can be reached via phone at +1-203-6247000.


MarketBeat Community Rating for Achillion Pharmaceuticals (ACHN)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  349 (Vote Outperform)
Underperform Votes:  265 (Vote Underperform)
Total Votes:  614
MarketBeat's community ratings are surveys of what our community members think about Achillion Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Achillion Pharmaceuticals (NASDAQ:ACHN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldBuyBuyBuy
Consensus Rating Score: 2.432.502.502.63
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.00$5.30$5.50$8.71
Price Target Upside: 71.23% upside80.58% upside42.49% upside81.17% upside

Achillion Pharmaceuticals (NASDAQ:ACHN) Consensus Price Target History

Price Target History for Achillion Pharmaceuticals (NASDAQ:ACHN)

Achillion Pharmaceuticals (NASDAQ:ACHN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/8/2018B. RileyInitiated CoverageNeutral -> Neutral$3.50MediumView Rating Details
12/11/2017Leerink SwannReiterated RatingBuy$5.00MediumView Rating Details
9/17/2017Chardan CapitalReiterated RatingNeutralHighView Rating Details
9/12/2017Ladenburg Thalmann Financial ServicesLower Price TargetBuy -> Buy$9.00 -> $6.50HighView Rating Details
9/12/2017Robert W. BairdReiterated RatingNeutral$5.00 -> $4.00HighView Rating Details
8/9/2017Maxim GroupSet Price TargetBuy$5.00 -> $7.00HighView Rating Details
4/26/2017Jefferies GroupReiterated RatingHoldLowView Rating Details
11/3/2016WedbushReiterated RatingOutperform$13.00N/AView Rating Details
9/15/2016FBR & CoInitiated CoverageOutperform$16.00N/AView Rating Details
7/7/2016JMP SecuritiesUpgradeMarket Perform -> Outperform$13.00N/AView Rating Details
(Data available from 2/23/2016 forward)

Earnings

Achillion Pharmaceuticals (NASDAQ:ACHN) Earnings History and Estimates Chart

Earnings by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Achillion Pharmaceuticals (NASDAQ ACHN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/22/2018Q4 2017($0.16)($0.17)ViewListenView Earnings Details
11/1/2017Q3 2017($0.18)($0.14)ViewN/AView Earnings Details
8/8/2017Q2 2017($0.16)($0.16)ViewListenView Earnings Details
5/4/2017Q1 2017($0.16)($0.15)ViewN/AView Earnings Details
2/23/2017Q4 2016($0.18)($0.03)$15.00 millionViewN/AView Earnings Details
11/3/2016Q3($0.16)($0.15)ViewN/AView Earnings Details
8/4/2016Q2($0.15)($0.14)ViewN/AView Earnings Details
5/3/2016Q116($0.14)($0.13)ViewN/AView Earnings Details
2/25/2016Q4$0.09$0.12$31.40 million$31.60 millionViewN/AView Earnings Details
11/5/2015Q3$0.09$0.19$32.62 million$33.82 millionViewN/AView Earnings Details
8/10/2015Q2($0.18)($0.25)$0.71 millionViewN/AView Earnings Details
5/7/2015Q115($0.22)($0.17)ViewN/AView Earnings Details
3/5/2015Q414($0.19)($0.21)ViewN/AView Earnings Details
11/4/2014Q314($0.18)($0.16)ViewN/AView Earnings Details
8/7/2014Q214($0.18)($0.16)ViewN/AView Earnings Details
5/7/2014Q114($0.17)($0.17)ViewN/AView Earnings Details
3/7/2014Q413($0.16)($0.14)$0.01 millionViewN/AView Earnings Details
11/12/2013Q3($0.20)($0.14)ViewN/AView Earnings Details
8/7/2013Q2 2013($0.16)($0.21)ViewN/AView Earnings Details
5/7/2013Q113($0.15)($0.14)ViewN/AView Earnings Details
2/20/2013Q4 2012($0.19)($0.14)ViewN/AView Earnings Details
11/8/2012Q312($0.17)($0.20)ViewN/AView Earnings Details
8/8/2012Q2 2012($0.17)($0.16)ViewN/AView Earnings Details
5/9/2012Q1 2012($0.15)($0.13)ViewN/AView Earnings Details
3/8/2012Q4 2011($0.16)($0.18)ViewN/AView Earnings Details
11/8/2011Q3 2011($0.17)($0.15)ViewN/AView Earnings Details
8/8/2011Q2 2011($0.17)($0.19)ViewN/AView Earnings Details
5/4/2011Q1 2011($0.14)($0.17)ViewN/AView Earnings Details
3/2/2011Q4 2010($0.13)($0.11)ViewN/AView Earnings Details
10/27/2010Q3 2010($0.15)($0.15)ViewN/AView Earnings Details
8/13/2010Q2 2010($0.17)($0.17)ViewN/AView Earnings Details
5/10/2010Q1 2010($0.20)($0.16)ViewN/AView Earnings Details
3/12/2010Q4 2009($0.22)($0.25)ViewN/AView Earnings Details
11/6/2009Q3 2009($0.21)($0.23)ViewN/AView Earnings Details
7/30/2009Q2 2009($0.25)($0.23)ViewN/AView Earnings Details
5/15/2009Q1 2009($0.25)($0.25)ViewN/AView Earnings Details
3/25/2009Q4 2008($0.28)($0.33)ViewN/AView Earnings Details
10/28/2008Q3 2008($0.28)($0.31)ViewN/AView Earnings Details
8/12/2008Q2 2008($0.38)($0.43)ViewN/AView Earnings Details
5/7/2008Q1 2008($0.38)($0.38)ViewN/AView Earnings Details
2/27/2008Q4 2007($0.45)($0.44)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Achillion Pharmaceuticals (NASDAQ:ACHN) Earnings Estimates

2018 EPS Consensus Estimate: ($0.74)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.17)($0.16)($0.17)
Q2 20182($0.19)($0.17)($0.18)
Q3 20182($0.21)($0.17)($0.19)
Q4 20182($0.22)($0.18)($0.20)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Achillion Pharmaceuticals (NASDAQ:ACHN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Achillion Pharmaceuticals (NASDAQ ACHN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.24%
Institutional Ownership Percentage: 78.75%
Insider Trades by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)
Institutional Ownership by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Achillion Pharmaceuticals (NASDAQ ACHN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/20/2017& Johnson JohnsonMajor ShareholderSell18,367,346$2.75$50,510,201.50View SEC Filing  
12/22/2016Jason S FishermanDirectorBuy10,000$3.96$39,600.0050,000View SEC Filing  
12/5/2016Mary Kay FentonCFOBuy2,500$4.11$10,275.002,500View SEC Filing  
12/2/2016Joel C BarrishInsiderBuy2,500$4.06$10,150.002,500View SEC Filing  
12/30/2015David ApelianinsiderSell10,000$10.50$105,000.00View SEC Filing  
12/28/2015Mary Kay FentonCFOSell43,500$10.08$438,480.00View SEC Filing  
11/11/2015Nicole VitulloDirectorSell550,000$10.17$5,593,500.0031,431View SEC Filing  
9/25/2015Nicole VitulloDirectorSell9,310$8.22$76,528.2031,431View SEC Filing  
1/23/2015Mary Kay FentonCFOSell13,125$16.00$210,000.00View SEC Filing  
1/21/2015Milind DeshpandeCEOSell100,000$15.00$1,500,000.00View SEC Filing  
9/30/2014Ra Capital Management, LlcInsiderSell1,332,014$10.20$13,586,542.80View SEC Filing  
9/29/2014Ra Capital Management, LlcInsiderSell221,014$10.96$2,422,313.44View SEC Filing  
9/26/2014Ra Capital Management, LlcMajor ShareholderSell2,372,915$11.17$26,505,460.55View SEC Filing  
9/25/2014Ra Capital Management, LlcMajor ShareholderSell497,986$11.05$5,502,745.30View SEC Filing  
9/24/2014Ra Capital Management, LlcMajor ShareholderSell1,204,929$11.27$13,579,549.83View SEC Filing  
9/23/2014Ra Capital Management, LlcMajor ShareholderSell2,595,071$11.29$29,298,351.59View SEC Filing  
9/2/2014Ra Capital Management, LlcMajor ShareholderSell835,293$11.63$9,714,457.59View SEC Filing  
8/27/2014Ra Capital Management, LlcMajor ShareholderSell2,711,352$11.33$30,719,618.16View SEC Filing  
8/26/2014Ra Capital Management, LlcMajor ShareholderSell2,112,867$11.35$23,981,040.45View SEC Filing  
8/25/2014Joseph TruittEVPSell25,000$10.82$270,500.00View SEC Filing  
8/25/2014Ra Capital Management, LlcMajor ShareholderSell331,396$10.96$3,632,100.16View SEC Filing  
8/18/2014Milind DeshpandeCEOSell216,624$10.00$2,166,240.00View SEC Filing  
8/18/2014Ra Capital Management, LlcMajor ShareholderSell4,235,000$9.53$40,359,550.00View SEC Filing  
8/15/2014Michael D KishbauchDirectorSell495,812$9.40$4,660,632.80View SEC Filing  
8/13/2014Gary E FrashierDirectorSell5,000$8.00$40,000.00View SEC Filing  
6/20/2014Ra Capital Management, LlcInsiderSell880,000$8.40$7,392,000.00View SEC Filing  
6/16/2014Gary E FrashierDirectorSell55,000$8.00$440,000.00View SEC Filing  
6/16/2014Joseph TruittEVPSell25,000$7.82$195,500.00View SEC Filing  
6/16/2014Qvt Associates Gp LlcMajor ShareholderSell1,819,551$7.70$14,010,542.70View SEC Filing  
6/11/2014Qvt Associates Gp LlcMajor ShareholderSell128,649$7.66$985,451.34View SEC Filing  
6/10/2014Joseph TruittEVPSell50,000$6.02$301,000.00View SEC Filing  
6/10/2014Michael D KishbauchDirectorSell371,937$7.75$2,882,511.75View SEC Filing  
12/30/2013Qvt Associates Gp Llcmajor shareholderSell170,239$3.34$568,598.26View SEC Filing  
12/26/2013Qvt Associates Gp Llcmajor shareholderSell121,205$3.44$416,945.20View SEC Filing  
12/23/2013Qvt Associates Gp Llcmajor shareholderSell289,141$3.24$936,816.84View SEC Filing  
12/19/2013Qvt Associates Gp Llcmajor shareholderSell222,612$3.09$687,871.08View SEC Filing  
12/17/2013Qvt Associates Gp Llcmajor shareholderSell92,803$3.11$288,617.33View SEC Filing  
11/22/2013Dennis LiottaDirectorBuy10,000$2.98$29,800.00100,000View SEC Filing  
11/20/2013Ra Capital Management, LlcInsiderBuy1,110,000$2.55$2,830,500.00View SEC Filing  
11/19/2013Jason FishermanDirectorBuy15,000$2.63$39,450.0040,000View SEC Filing  
11/12/2013Ra Capital Management, LlcInsiderBuy1,795,000$2.48$4,451,600.00View SEC Filing  
10/31/2013Ra Capital Management, LlcInsiderBuy1,186,007$2.45$2,905,717.15View SEC Filing  
10/14/2013Ra Capital Management, LlcInsiderBuy2,369,229$2.79$6,610,148.91View SEC Filing  
10/11/2013Ra Capital Management, LlcInsiderBuy2,448,710$2.56$6,268,697.60View SEC Filing  
9/30/2013Ra Capital Management, LlcInsiderBuy2,800,000$2.98$8,344,000.00View SEC Filing  
8/14/2013Jason FishermanDirectorBuy5,000$6.83$34,150.0025,000View SEC Filing  
8/12/2013Dennis LiottaDirectorBuy5,000$6.47$32,350.0090,000View SEC Filing  
8/9/2013Qvt Associates Gp Llcmajor shareholderBuy102,282$6.41$655,627.62View SEC Filing  
7/11/2013Qvt Associates Gp LlcMajor ShareholderBuy401,017$6.46$2,590,569.82View SEC Filing  
7/10/2013Qvt Associates Gp LlcMajor ShareholderBuy390,944$6.33$2,474,675.52View SEC Filing  
7/8/2013Qvt Associates Gp LlcMajor ShareholderBuy642,509$6.28$4,034,956.52View SEC Filing  
7/3/2013Qvt Associates Gp LlcMajor ShareholderBuy1,963,248$6.43$12,623,684.64View SEC Filing  
7/1/2013Gary E FrashierDirectorSell5,000$8.17$40,850.00View SEC Filing  
6/21/2013Jason S FishermanDirectorBuy10,000$7.63$76,300.00View SEC Filing  
6/7/2013Gary E FrashierDirectorSell5,000$8.37$41,850.00View SEC Filing  
6/3/2013Jason S FishermanDirectorBuy10,000$7.87$78,700.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Achillion Pharmaceuticals (NASDAQ ACHN) News Headlines

Source:
DateHeadline
Achillion (ACHN) Q4 Loss Widens, Plans Job Cuts to Save CostAchillion (ACHN) Q4 Loss Widens, Plans Job Cuts to Save Cost
www.zacks.com - February 23 at 8:39 AM
Form 8-K ACHILLION PHARMACEUTICAL For: Feb 22Form 8-K ACHILLION PHARMACEUTICAL For: Feb 22
www.streetinsider.com - February 22 at 5:27 PM
Was Achillion Pharmaceuticals Inc’s (NASDAQ:ACHN) Earnings Decline A Part Of Broader Industry Downturn?Was Achillion Pharmaceuticals Inc’s (NASDAQ:ACHN) Earnings Decline A Part Of Broader Industry Downturn?
finance.yahoo.com - February 22 at 5:27 PM
Achillion Pharmaceuticals (ACHN) Announces Quarterly  Earnings Results, Misses Estimates By $0.01 EPSAchillion Pharmaceuticals (ACHN) Announces Quarterly Earnings Results, Misses Estimates By $0.01 EPS
www.americanbankingnews.com - February 22 at 10:50 AM
Achillion Pharmaceuticals (ACHN) Updates FY18 Earnings GuidanceAchillion Pharmaceuticals (ACHN) Updates FY18 Earnings Guidance
www.americanbankingnews.com - February 22 at 10:09 AM
Achillion Pharmaceuticals (ACHN) Upgraded by BidaskClub to "Hold"Achillion Pharmaceuticals (ACHN) Upgraded by BidaskClub to "Hold"
www.americanbankingnews.com - February 19 at 3:38 PM
Achillion to Present at the Leerink Partners 7th Annual Global Healthcare ConferenceAchillion to Present at the Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 17 at 8:25 AM
Achillion Pharmaceuticals, Inc. Expected to Earn FY2017 Earnings of ($0.59) Per Share (ACHN)Achillion Pharmaceuticals, Inc. Expected to Earn FY2017 Earnings of ($0.59) Per Share (ACHN)
www.americanbankingnews.com - February 12 at 1:08 AM
Achillion Pharmaceuticals (ACHN) Research Coverage Started at B. RileyAchillion Pharmaceuticals (ACHN) Research Coverage Started at B. Riley
www.americanbankingnews.com - February 11 at 3:24 PM
Achillion Pharmaceuticals, Inc. (ACHN) Receives Average Rating of "Hold" from AnalystsAchillion Pharmaceuticals, Inc. (ACHN) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - February 2 at 12:34 PM
Achillion Pharmaceuticals, Inc. (ACHN) Expected to Announce Earnings of -$0.15 Per ShareAchillion Pharmaceuticals, Inc. (ACHN) Expected to Announce Earnings of -$0.15 Per Share
www.americanbankingnews.com - January 23 at 11:06 PM
Achillion Pharmaceuticals (ACHN) Stock Rating Lowered by BidaskClubAchillion Pharmaceuticals (ACHN) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - January 13 at 6:28 PM
Achillion Pharmaceuticals: Ultra-Rare Disease Company With Ultra-Rare Enterprise Value - Seeking AlphaAchillion Pharmaceuticals: Ultra-Rare Disease Company With Ultra-Rare Enterprise Value - Seeking Alpha
seekingalpha.com - January 10 at 6:36 AM
Achillion Pharmaceuticals, Inc. (ACHN) Given Consensus Recommendation of "Hold" by BrokeragesAchillion Pharmaceuticals, Inc. (ACHN) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - January 8 at 8:38 AM
Technical Perspectives on Cytokinetics, Geron, Achillion Pharma, and Calithera Biosciences - PR Newswire (press release)Technical Perspectives on Cytokinetics, Geron, Achillion Pharma, and Calithera Biosciences - PR Newswire (press release)
www.prnewswire.com - December 29 at 9:24 AM
Alexion's (ALXN) Soliris Label Expansion Approved in JapanAlexion's (ALXN) Soliris Label Expansion Approved in Japan
finance.yahoo.com - December 27 at 9:54 AM
BioMarins (BMRN) Pegvaliase Review Period Extended by FDABioMarin's (BMRN) Pegvaliase Review Period Extended by FDA
finance.yahoo.com - December 26 at 11:29 PM
Achillion Pharmaceuticals (ACHN) Raised to "Sell" at BidaskClubAchillion Pharmaceuticals (ACHN) Raised to "Sell" at BidaskClub
www.americanbankingnews.com - December 23 at 5:04 PM
CORRECTION - Achillion Pharmaceuticals, Inc.CORRECTION - Achillion Pharmaceuticals, Inc.
finance.yahoo.com - December 20 at 3:18 PM
Achillion Pharma (ACHN) Commences Phase I First-In Study of ACH-5228 - StreetInsider.comAchillion Pharma (ACHN) Commences Phase I First-In Study of ACH-5228 - StreetInsider.com
www.streetinsider.com - December 20 at 6:15 AM
Achillion Initiates Phase I First-In Study of ACH-5228, a Next-Generation Oral Small Molecule Inhibitor of Complement Factor DAchillion Initiates Phase I First-In Study of ACH-5228, a Next-Generation Oral Small Molecule Inhibitor of Complement Factor D
finance.yahoo.com - December 20 at 6:15 AM
Achillions Renal Disease Candidate Gets Orphan Drug StatusAchillion's Renal Disease Candidate Gets Orphan Drug Status
www.nasdaq.com - December 19 at 3:18 PM
Achillion Pharma (ACHN) Granted FDA Orphan Drug Designation for ACH-4471 & Initiation of Phase 1 Extended ... - StreetInsider.comAchillion Pharma (ACHN) Granted FDA Orphan Drug Designation for ACH-4471 & Initiation of Phase 1 Extended ... - StreetInsider.com
www.streetinsider.com - December 19 at 6:30 AM
Twitter Up 5% on Better RatingTwitter Up 5% on Better Rating
finance.yahoo.com - December 18 at 3:18 PM
UPDATE: Achillion Pharma (ACHN) Defended at Leerink - StreetInsider.comUPDATE: Achillion Pharma (ACHN) Defended at Leerink - StreetInsider.com
www.streetinsider.com - December 16 at 6:25 AM
Achillion Pharmaceuticals, Inc. (ACHN) Short Interest Down 18.3% in NovemberAchillion Pharmaceuticals, Inc. (ACHN) Short Interest Down 18.3% in November
www.americanbankingnews.com - December 15 at 2:38 AM
Achillion Pharmaceuticals, Inc. (ACHN) Receives Consensus Recommendation of "Hold" from AnalystsAchillion Pharmaceuticals, Inc. (ACHN) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - December 14 at 8:42 AM
Achillion Pharmaceuticals, Inc. (ACHN) Expected to Earn Q1 2018 Earnings of ($0.16) Per ShareAchillion Pharmaceuticals, Inc. (ACHN) Expected to Earn Q1 2018 Earnings of ($0.16) Per Share
www.americanbankingnews.com - December 12 at 9:58 AM
Achillion Pharmaceuticals (ACHN) Receives Buy Rating from Leerink SwannAchillion Pharmaceuticals (ACHN) Receives Buy Rating from Leerink Swann
www.americanbankingnews.com - December 11 at 5:08 PM
Revances Neuromodulator Injection Positive in Phase IIIRevance's Neuromodulator Injection Positive in Phase III
finance.yahoo.com - December 6 at 3:18 PM
Revance's Neuromodulator Injection Positive in Phase IIIRevance's Neuromodulator Injection Positive in Phase III
finance.yahoo.com - December 6 at 3:18 PM
-$0.15 EPS Expected for Achillion Pharmaceuticals, Inc. (ACHN) This Quarter-$0.15 EPS Expected for Achillion Pharmaceuticals, Inc. (ACHN) This Quarter
www.americanbankingnews.com - December 3 at 1:32 PM
Celldex Begins Phase I Trial on Cancer Candidate CDX-1140Celldex Begins Phase I Trial on Cancer Candidate CDX-1140
finance.yahoo.com - December 2 at 7:51 AM
[$$] J&J Lost $175 Million on Achillion Stock Investment[$$] J&J Lost $175 Million on Achillion Stock Investment
finance.yahoo.com - November 27 at 3:17 PM
Achillion Pharmaceuticals, Inc. (ACHN) Upgraded to "Buy" at Zacks Investment ResearchAchillion Pharmaceuticals, Inc. (ACHN) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - November 26 at 10:30 PM
Puma Inks License Deal to Commercialize Cancer Drug NerlynxPuma Inks License Deal to Commercialize Cancer Drug Nerlynx
finance.yahoo.com - November 23 at 3:21 PM
Glaxo (GSK) Files for U.S. Label Expansion of COPD InhalerGlaxo (GSK) Files for U.S. Label Expansion of COPD Inhaler
finance.yahoo.com - November 23 at 3:21 PM
Achillion Pharmaceuticals, Inc. (ACHN) Major Shareholder Sells $50,510,201.50 in StockAchillion Pharmaceuticals, Inc. (ACHN) Major Shareholder Sells $50,510,201.50 in Stock
www.americanbankingnews.com - November 22 at 1:36 PM
Agios Posts New Data on Glioma Candidate from Dose ExpansionAgios Posts New Data on Glioma Candidate from Dose Expansion
finance.yahoo.com - November 20 at 4:59 PM
Head-To-Head Contrast: Achillion Pharmaceuticals (ACHN) & The CompetitionHead-To-Head Contrast: Achillion Pharmaceuticals (ACHN) & The Competition
www.americanbankingnews.com - November 20 at 11:19 AM
Achillion Pharmaceuticals, Inc. (ACHN) Given Average Recommendation of "Hold" by BrokeragesAchillion Pharmaceuticals, Inc. (ACHN) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 19 at 7:56 AM
Here's Why Achillion Pharmaceuticals Is Soaring 19.5% TodayHere's Why Achillion Pharmaceuticals Is Soaring 19.5% Today
finance.yahoo.com - November 16 at 8:41 PM
First Week Of June 2018 Options Trading For Achillion Pharmaceuticals (ACHN)First Week Of June 2018 Options Trading For Achillion Pharmaceuticals (ACHN)
www.thestreet.com - November 16 at 3:37 PM
Achillion Pharma (ACHN) Prices 18.37M Share Common Secondary Offering by Johnson & Johnson (JNJ) at $2.75/ShAchillion Pharma (ACHN) Prices 18.37M Share Common Secondary Offering by Johnson & Johnson (JNJ) at $2.75/Sh
www.streetinsider.com - November 16 at 3:37 PM
Pre-Market Most Active for Nov 16, 2017 : ACHN, TVIX, BBY, CSCO, WMT, HMC, ROKU, BAC, GE, NOK, QQQ, AAPL - NasdaqPre-Market Most Active for Nov 16, 2017 : ACHN, TVIX, BBY, CSCO, WMT, HMC, ROKU, BAC, GE, NOK, QQQ, AAPL - Nasdaq
www.nasdaq.com - November 16 at 10:38 AM
Achillion Announces Pricing of Secondary Offering Of Common Stock - GlobeNewswire (press release)Achillion Announces Pricing of Secondary Offering Of Common Stock - GlobeNewswire (press release)
globenewswire.com - November 16 at 10:38 AM
Biotech Stock Roundup: Dynavax Vaccine Gets FDA Nod, Loxo Inks Deal with BayerBiotech Stock Roundup: Dynavax Vaccine Gets FDA Nod, Loxo Inks Deal with Bayer
finance.yahoo.com - November 16 at 10:38 AM
Achillion Heel: Stock Plunges as J&J ExitsAchillion Heel: Stock Plunges as J&J Exits
finance.yahoo.com - November 16 at 10:38 AM
Achillion (ACHN) Shares Down as J&J Announces Stake SaleAchillion (ACHN) Shares Down as J&J Announces Stake Sale
finance.yahoo.com - November 16 at 10:38 AM
Why Achillion Pharmaceuticals Stock Is Falling TodayWhy Achillion Pharmaceuticals Stock Is Falling Today
finance.yahoo.com - November 16 at 10:38 AM

SEC Filings

Achillion Pharmaceuticals (NASDAQ:ACHN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Achillion Pharmaceuticals (NASDAQ:ACHN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Achillion Pharmaceuticals (NASDAQ ACHN) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.